A Qualitative Transcriptional Signature for Predicting Extreme Resistance of ER-Negative Breast Cancer to Paclitaxel, Doxorubicin, and Cyclophosphamide Neoadjuvant Chemotherapy

For estrogen receptor (ER)-negative breast cancer patients, paclitaxel (P), doxorubicin (A) and cyclophosphamide (C) neoadjuvant chemotherapy (NAC) is the standard therapeutic regimen. Pathologic complete response (pCR) and residual disease (RD) are common surrogate measures of chemosensitivity. Aft...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Front Mol Biosci
Asıl Yazarlar: Chen, Yanhua, Cai, Hao, Chen, Wannan, Guan, Qingzhou, He, Jun, Guo, Zheng, Li, Jing
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Frontiers Media S.A. 2020
Konular:
Molecular Biosciences
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7109260/
https://ncbi.nlm.nih.gov/pubmed/32269999
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fmolb.2020.00034
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller